TrialJournal for immunotherapy of cancer2023

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.

Caicun Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.